Group 1: Financial Performance - In 2025, the company achieved a revenue of 9.784 billion yuan, a year-on-year decrease of 18.62% [3] - The net profit attributable to shareholders was 891 million yuan, down 13.62% year-on-year; the net profit after deducting non-recurring gains and losses was 769 million yuan, a decrease of 21.86% [3] - The raw material drug segment reported a revenue of 6.165 billion yuan, a decline of 28.74% year-on-year, with a gross profit of 834 million yuan, down 35.59% [5] - The pharmaceutical segment generated a revenue of 1.155 billion yuan, a decrease of 18.42%, with a gross profit of 708 million yuan, down 7.3% [6] Group 2: CDMO Business Growth - The CDMO segment achieved a revenue of 2.198 billion yuan, a year-on-year increase of 16.66%, with a gross profit of 994 million yuan, up 28.54% [3] - The gross margin for the CDMO segment was 45.24%, an increase of 4.18 percentage points year-on-year [3] - The number of ongoing CDMO projects reached 1,311, a 32% increase year-on-year, with 398 commercialized projects, up 12% [4] - The company has signed confidentiality agreements with 713 innovative drug companies, an increase of 141 from the previous year [4] Group 3: R&D and Innovation - R&D expenditure for 2025 was 659 million yuan, a year-on-year increase of 2.79% [7] - The company has 1,326 R&D personnel, with 55 holding PhDs and 559 holding master's degrees, making up nearly 20% of the workforce [7] - The company plans to maintain a steady annual increase of 5% to 8% in R&D investment to support CDMO business growth and new technology fields [12] Group 4: Market Conditions and Challenges - The pharmaceutical industry environment remains challenging, heavily influenced by industry policies, particularly centralized procurement [3] - The overall raw material drug industry is in a downturn, with significant price pressures affecting sales [5] - The company anticipates continued improvement in the raw material drug business in 2026 after a challenging 2025 [6] Group 5: Future Outlook - The company expects to deliver over 6 billion yuan in commercialized orders within the next three years for the CDMO business [11] - The company aims to scale its medical beauty and cosmetic raw materials business to 1 billion yuan within three to five years [10] - The company plans to balance shareholder returns with the funding needs for CDMO business expansion, with over 92% of profits allocated for dividends in 2025 [15]

Core Insights - The 34th European Academy of Dermatology and Venereology (EADV 2025) concluded successfully in Paris, where the Chinese beauty brand, Shangmei Co., made a significant debut by releasing the "2025 KANSU Peptide Research and Efficacy Skincare Application Yearbook" [1] - This publication, which encapsulates 22 years of research on peptides by KANSU, was also showcased at the 2025 China Fragrance and Cosmetic Industry Annual Conference and Expo (CAME), highlighting China's innovative contributions to anti-aging solutions [1] Group 1 - The "KANSU Peptide Yearbook" is edited by renowned dermatology experts, showcasing the brand's deep commitment to peptide research and establishing its credibility in the field [3] - The yearbook serves as a practical guide for consumers and a testament to the brand's long-term commitment to scientific development in the industry [6] - It outlines a comprehensive framework that combines global perspectives with local insights, detailing over 50 years of peptide technology evolution [6] Group 2 - The yearbook presents significant market transformation results, with the "Red Waist 2.0" series showing a 38.57% reduction in cheek wrinkle length and a 33.83% increase in skin hydration [7] - The KANSU X Peptide Super Frequency Cream demonstrated a 27.59% increase in collagen and a 30.57% improvement in elastin after 28 days of testing, setting new industry benchmarks [7] - These quantifiable results address the industry's challenge of measuring anti-aging effects, providing consumers with clear efficacy references [7] Group 3 - The yearbook emphasizes the importance of long-term research investment in building core competitiveness in the anti-aging sector, reflecting on the industry's short-termism [10] - It documents KANSU's journey from initiating peptide research in 2003 to achieving significant milestones in innovation and application [11] - The yearbook's authority stems from KANSU's unique research accumulation and international recognition, showcasing a robust peptide research system [11] Group 4 - Karl Lintner, a pioneer in peptide technology, praised KANSU's application of cyclic peptides, affirming its contributions to foundational research and product development [13] - The dual launch at EADV and CAME signifies KANSU's strategic positioning to engage globally while remaining rooted in China [13] - The yearbook sets future goals for KANSU to leverage AI and computational biology in advancing peptide research, marking a transition from "Made in China" to "Intelligent Manufacturing in China" [13]